Galapagos NV

25.31

13-June-25 08:17:35

15 minutes delayed

Stocks

+0.43

+1.73%

Today's range

24.70 - 25.32

ISIN

BE0003818359

Source

Cboe

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

22 Aug 2024 22:00:00 By Nasdaq GlobeNewswire
Galapagos receives transparency notification from FMR LLC

20 Aug 2024 13:01:00 By Nasdaq GlobeNewswire
Galapagos reports half-year 2024 financial results and provides second quarter business update

01 Aug 2024 13:01:00 By Nasdaq GlobeNewswire
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

14 Jun 2024 13:01:00 By Nasdaq GlobeNewswire
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

30 May 2024 13:01:00 By Nasdaq GlobeNewswire
Galapagos creates new subscription right plans

16 May 2024 13:01:00 By Nasdaq GlobeNewswire
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.

15 May 2024 13:01:00 By Nasdaq GlobeNewswire
Galapagos reports first quarter 2024 financial results

02 May 2024 13:01:00 By Nasdaq GlobeNewswire
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024

30 Apr 2024 13:01:00 By Nasdaq GlobeNewswire
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

04 Apr 2024 13:01:00 By Nasdaq GlobeNewswire
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings

28 Mar 2024 13:01:00 By Nasdaq GlobeNewswire
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

26 Mar 2024 13:01:00 By Nasdaq GlobeNewswire
Galapagos announces full year 2023 results and outlook for 2024

22 Feb 2024 13:01:00 By Nasdaq GlobeNewswire
Galapagos presents at EBMT-EHA annual meeting 2024

15 Feb 2024 13:01:00 By Nasdaq GlobeNewswire
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

31 Jan 2024 13:01:00 By Nasdaq GlobeNewswire
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.

04 Jan 2024 13:01:00 By Nasdaq GlobeNewswire
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

03 Jan 2024 13:01:00 By Nasdaq GlobeNewswire
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma

01 Jan 2024 22:00:00 By Nasdaq GlobeNewswire
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301

19 Dec 2023 13:01:00 By Nasdaq GlobeNewswire
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101

09 Dec 2023 09:00:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.